This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.
SCIENTIFIC ADVISORY BOARD

SCIENTIFIC ADVISORY BOARD

ABOUT US

About Admin

This author has not yet filled in any details.
So far Admin has created 13 blog entries.

Scientific Advisory Board

By |October 19th, 2017|Uncategorized|

NASH AND PSC SYSTEMIC SCLEROSIS

Comments Off on Scientific Advisory Board

Scientific Advisory Board

By |October 19th, 2017|Uncategorized|

Comments Off on Scientific Advisory Board

NASH and PSC

By |October 18th, 2017|About us|

Scott L. Friedman MD, Icahn School of Medicine at Mount Sinai hospital, New York, USA Dr. Friedman is Chief of Liver Diseases and Dean for Therapeutic Discovery at the Icahn School of Medicine at Mount Sinai.  His pioneering research in hepatic fibrosis supported by NIH since 1986, combined with mentoring of over 80 trainees have [...]

Comments Off on NASH and PSC

Systemic sclerosis

By |March 6th, 2017|About us|

Cheif of Advisory Board- Marco Matucci Cerinic MD, PhD, FRCP, FBSRhon, University of Florence, Florence, Italy Marco Matucci-Cerinic is Professor of Rheumatology and Medicine at the Department of Musculoskeletal Medicine , and Director of the Rheumatology Department AVC and of the Division of Rheumatology AOUC, at the Azienda Ospedaliera Universitaria Careggi in Florence, Italy. Dr [...]

Comments Off on Systemic sclerosis

News & updates

By |February 28th, 2016|Uncategorized|

April 2018 ChemomAb presents "A novel CCL24 blocking monoclonal antibody ameliorates liver injury in experimental models of cholestasis" at EASL International Liver Congress 2018. March 2018 ChemomAb successfully completed Phase 1 in healthy volunteers, achieving its primary endpoint of safety, pharmacokinetics and pharmacodynamics. November 2017 ChemomAb completed a $10 million series B fund raising supported [...]

Comments Off on News & updates

Publications

By |February 28th, 2016|Research & Developement|

Ablin M. Entin-Meer V. Aloush S. et al. Protective effect of eotaxin-2 inhibition in adjuvant-induced arthritis. Clinical and Experimental Immunology. 2010; V161(2):276–83. Mausner-Fainberg K, Karni A, George J, et al. Eotaxin-2 blockade ameliorates experimental autoimmune encephalomyelitis. World J. Immunol. 2013 Mar; 3(1):7-14. Mor A, Afek A, Entin-Meer M, Keren G, George J. Anti eotaxin-2 antibodies [...]

Comments Off on Publications

Indications

By |February 28th, 2016|Research & Developement|

Nonalcoholic steatohepatitis (NASH) Nonalcoholic steatohepatitis or NASH is a common liver disease. It resembles alcoholic liver disease but occurs in people who drink little or no alcohol. The pathophysiology involves fat accumulation (steatosis), inflammation, and, variably, fibrosis. Steatosis results from hepatic triglyceride accumulation. Most patients are asymptomatic. However, some have fatigue, malaise, or right upper [...]

Comments Off on Indications

Lead Product

By |February 28th, 2016|Research & Developement|

CM101 is a first in class monoclonal antibody directed against a novel target found to be involved in inflammatory and fibrotic processes. CM-101 has completed seven years of various pre-clinical testing in-vitro, ex-vivo and in-vivo in several animal models.  CM101 has been shown to be beneficial in multiple experimental models of NASH, PSC and systemic [...]

Comments Off on Lead Product

Scientific Overview

By |February 28th, 2016|Research & Developement|

ChemomAb identified a novel chemokine pathway that mediates inflammation and fibrosis and subsequently developed proprietary antibodies that target it.  Compelling data has been gathered on the efficacy of ChemomAb’s lead compound in models of nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC)  and systemic sclerosis. CM-101 is the lead monoclonal anti-chemokine antibody that binds  a unique [...]

Comments Off on Scientific Overview

Board of Directors

By |February 28th, 2016|Uncategorized|

Nissim Darvish,  Nissim Darvish is a Senior Managing Director of Orbimed Venture Capital. Nissim is a veteran of the life science industry, with fifteen years of experience covering medical technology development, corporate leadership, and investment management. Nissim spent eight years with Pitango, where he was a general partner managing investments in life sciences. Previously, Nissim [...]

Comments Off on Board of Directors